 Novan, Inc. the Company or Novan NOVN today announced that it has engaged H.C. Wainwright Co., LLC H.C. Wainwright Co. to assist the Company in exploring and evaluating a range of strategic and financial alternatives, intended to maximize shareholder value. The Company has advanced several late stage development programs in the field of dermatology, including the Companys lead product candidate, SB206, that is in Phase 3 clinical trials for molluscum contagiosum molluscum, a primarily pediatric contagious skin infection. 